Clinical Trial Update: HBsAg Decline After Pegylated-interferon-α in e Antigen Positive Chronic Hepatitis B With Nucleoside Maintenance [Phase 3]

View source ↗

Summary

Phase 3 trial update examining the decline of HBsAg with pegylated interferon-α in HBeAg-positive chronic hepatitis B with nucleoside maintenance.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis B

Drugs mentioned

• Pegylated interferon (pegylated interferon alfa)

Snippet

Sponsor: Pusan National University Hospital | Conditions: Chronic Hepatitis B | Phase 3 | Status: UNKNOWN